May even work on melanomas that have resisted treatment
An experimental cancer drug works differently than intended and shows significant promise for stopping melanoma and possibly other forms of cancer, research from the University of Virginia School of Medicine suggests. The findings also indicate the drug may be effective against melanomas that have resisted other forms of treatment.
The drug, pevonedistat, is already being tested in people. Scientists have been uncertain exactly how it kills cancer cells, as it shuts down many different cellular proteins – hundreds if not thousands. But the UVA researchers, led by Tarek Abbas, PhD, of the Department of Radiation Oncology and the UVA Cancer Center, have determined that the drug acts upon a particular protein that melanomas and other cancers rely on to replicate with great speed and deadly effect. By denying the cancers this essential ingredient, doctors may be able to stop melanomas and other forms of the disease.
“We think that this is what lets the cancer cells cope with the amount of replication they must undergo,” Abbas said. “They divide in uncontrolled fashion, and those cells that divide faster and more frequently are under tremendous replication stress, so these cancer cells needed to be able to develop a way to cope with that.”
The critical protein blocked by pevonedistat is produced by the gene CDT2, and it is vital for malignant cancer cells to survive. Without it, the cells stop replicating and begin to fall apart. “We have great understanding now for how the drug works,” Abbas said. “And we think the drug works not because of its intended target, but rather because it works on [the CDT2 protein] way downstream of that.”
Excessive amounts of the protein are produced in melanoma cells, and patients with high levels of it are less likely to survive. “These tumors, and not necessarily just melanoma, they are addicted to this gene,” Abbas said. “And that makes them very susceptible to the drug. In fact, we showed, that melanoma cells that have higher levels of expression of CDT2 are much more susceptible to the drug.”
High levels of the CDT2 protein are also found in many other tumors, he noted, including brain, breast and liver tumors. Doctors may one day use the level of the protein as a way to gauge disease prognosis.
‘We Have Great Hope’
The safety and effectiveness of pevonedistat in people is still being tested, and it is not yet available as a treatment. But Abbas, who has not been involved in the drug’s testing, is optimistic based on his findings. “We have great hope that this drug will have very significant impact on melanoma in general. … In fact, the drug is very effective on all melanomas, including those for which an effective therapeutic is lacking,” he said. “We actually show this drug can work on melanoma that resisted treatment, which is a major challenge in melanoma therapy. … If approved by the FDA and it moves forward, this drug could potentially be a good second-line therapy for those patients that fail initial treatment.”
Learn more: Experimental drug could stop melanoma, other cancers, research suggests
The Latest on: Pevonedistat
Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030 - PR Newswire (press release)
December 2, 2016 - In fact, the two late stage molecules, idasanutlin and pevonedistat, are being developed for hematological cancers. Other indications such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia and Angelman syndrome are also gradually gaining ...
Takeda to present new data on haematology-oncology portfolio at ASH annual meeting - pharmabiz.com
November 5, 2016 - The company will share analyses on pevonedistat, a first-in-class selective inhibitor of the NEDD8-activating enzymes in a clinical trial for myelodysplastic syndromes and acute myeloid leukemia. This inhibitor disrupts cullin-ring ligase mediated ...
Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting - Business Wire (press release)
November 3, 2016 - The company will share analyses on pevonedistat, a first-in-class selective inhibitor of the NEDD8-activating enzymes in a clinical trial for myelodysplastic syndromes and acute myeloid leukemia. This inhibitor disrupts cullin-ring ligase mediated ...
Experimental Therapy Shows Notable Promise in Treating Melanoma and Other Cancers - Melanoma News Today
September 13, 2016 - It was previously thought that pevonedistat inhibited major signaling pathways in tumor cells, but the researchers found that this drug works by inhibiting the activation of CDT2, a protein that tumor cells rely on to replicate rapidly without ...
Melanoma may be stoppable with drug that halts cancer cell proliferation - Medical News Today
September 12, 2016 - A drug already being tested in people as a treatment for cancer appears to show great promise in halting melanoma skin cancer. The drug - called pevonedistat - works in a way differently than intended and could also be effective against other cancers.
Experimental Drug Could Stop Melanoma, UVA Research Suggests - UVA Today (press release) (registration)
September 7, 2016 - The drug, pevonedistat, is already being tested in people. Scientists have been uncertain exactly how it kills cancer cells, as it shuts down many different cellular proteins – hundreds, if not thousands. But the UVA researchers, led by Tarek Abbas of ...
UVA Research Suggests Experimental Drug Could Stop Melanoma - NBC 29 News
September 6, 2016 - Researchers at University of Virginia Cancer Center say an experimental drug could help to stop melanoma and other forms of cancer. The drug is called pevonedistat. Researchers found that the drug could stop melanoma cancer cells from replicating by ...
Mantle Cell Lymphoma Pipeline Research Report for H2 2015 - PR Newswire (press release)
December 3, 2015 - ... ONC-201, pevonedistat hydrochloride, polatuzumab vedotin, ribociclib, SEL-120, selinexor, SGN-CD70A, SL-101, Small Molecule for Mantle Cell Lymphoma, temsirolimus, TGR-1202, tisagenlecleucel-T, tretinoin, ublituximab, venetoclax and vorinostat.
Ligand Provides Highlights from Today's Analyst Day Event - Business Wire (press release)
November 18, 2015 - SAN DIEGO--(BUSINESS WIRE)--At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered ...
Pevonedistat May Be Safe, Active in Heavily Pretreated Patients With Lymphoma - Oncology Nurse Advisor
November 12, 2015 - Results from a phase 1 clinical trial suggest that pevonedistat, a NEDD8-activating enzyme inhibitor, is safe, tolerable, and has some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma, according to a new study ...